Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma

Biomaterials

Volumn 34, Issue 21, 2013, Pages 5149-5162

  Xu, Qingxing ^a,b   Leong, Jiayu ^a   Chua, Qi Yi ^a   Chi, Yu Tse ^a   Chow, Pierce Kah Hoe ^c,d,e   Pack, Daniel W ^b   Wang, Chi Hwa ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Chitosan; Double walled microspheres; Doxorubicin; P53; PLGA; PLLA

Indexed keywords

DOUBLE-WALLED MICROSPHERES; DOXORUBICIN; P53; PLGA; PLLA;

CELLS; CHEMOTHERAPY; CHITOSAN; COPOLYMERS; CYTOLOGY; DNA; EFFICIENCY; GENE ENCODING; GENE THERAPY; GENE TRANSFER; NANOPARTICLES; OPTIMIZATION; PROTEINS; TUMORS;

MICROSPHERES;

CASPASE 3; CHITOSAN; DOXORUBICIN; MICROSPHERE; POLYETHYLENEIMINE; PROTEIN P53;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CELL STRAIN HEPG2; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TRANSFER; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL DEATH; CELL SURVIVAL; CHITOSAN; COMBINED MODALITY THERAPY; DNA; DOXORUBICIN; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC THERAPY; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; LUCIFERASES; MICROSPHERES; NANOPARTICLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84877042224     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.03.044     Document Type: Article

References (44)

1. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
2. Vousden K.H., Lane D.P. p53 in health and disease. Nat Rev Mol Cell Biol 2007, 8:275-283.
3. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002, 19:607-614.
4. Xu L., Pirollo K.F., Chang E.H. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. JControl Release 2001, 74:115-128.
5. Wiradharma N., Tong Y.W., Yang Y.Y. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. Biomaterials 2009, 30:3100-3109.
6. Lu X., Wang Q.Q., Xu F.J., Tang G.P., Yang W.T. Acationic prodrug/therapeutic gene nanocomplex for the synergistic treatment of tumors. Biomaterials 2011, 32:4849-4856.
7. Thomas M.B., Zhu A.X. Hepatocellular carcinoma: the need for progress. JClin Oncol 2005, 23:2892-2899.
8. Choi D.H., Park C.H., Kim I.H., Chun H.J., Park K., Han D.K. Fabrication of core-shell microcapsules using PLGA and alginate for dual growth factor delivery system. JControl Release 2010, 147:193-201.
9. Nie H., Dong Z., Arifin D.Y., Hu Y., Wang C.H. Core/shell microspheres via coaxial electrohydrodynamic atomization for sequential and parallel release of drugs. JBiomed Mater Res A 2010, 95:709-716.
10. Nie H., Fu Y., Wang C.H. Paclitaxel and suramin-loaded core/shell microspheres in the treatment of brain tumors. Biomaterials 2010, 31:8732-8740.
11. Xu Q., Xia Y., Wang C.H., Pack D.W. Monodisperse double-walled microspheres loaded with chitosan-p53 nanoparticles and doxorubicin for combined gene therapy and chemotherapy. JControl Release 2012, 163:130-135.
12. Mao H.Q., Roy K., Troung-Le V.L., Janes K.A., Lin K.Y., Wang Y., et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. JControl Release 2001, 70:399-421.
13. Liu W., Sun S., Cao Z., Zhang X., Yao K., Lu W.W., et al. An investigation on the physicochemical properties of chitosan/DNA polyelectrolyte complexes. Biomaterials 2005, 26:2705-2711.
14. Kircheis R., Schüller S., Brunner S., Ogris M., Heider K.H., Zauner W., et al. Polycation-based DNA complexes for tumor-targeted gene delivery invivo. JGene Med 1999, 1:111-120.
15. Ogris M., Brunner S., Schüller S., Kircheis R., Wagner E. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther 1999, 6:595-605.
16. Köping-Höggård M., Tubulekas I., Guan H., Edwards K., Nilsson M., Vårum K.M., et al. Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine invitro and after lung administration invivo. Gene Ther 2001, 8:1108-1121.
17. Fischer D., Li Y., Ahlemeyer B., Krieglstein J., Kissel T. Invitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003, 24:1121-1131.
18. Choksakulnimitr S., Masuda S., Tokuda H., Takakura Y., Hashida M. Invitro cytotoxicity of macromolecules in different cell culture systems. JControl Release 1995, 34:233-241.
19. el-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992, 1:45-49.
20. Jimenez G.S., Khan S.H., Stommel J.M., Wahl G.M. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 1999, 18:7656-7665.
21. Kamada S., Kikkawa U., Tsujimoto Y., Hunter T. Nuclear translocation of caspase-3 is dependent on its proteolytic activation and recognition of a substrate-like protein(s). JBiol Chem 2005, 280:857-860.
22. Takemoto K., Nagai T., Miyawaki A., Miura M. Spatio-temporal activation of caspase revealed by indicator that is insensitive to environmental effects. JCell Biol 2003, 160:235-243.
23. Earnshaw W.C., Martins L.M., Kaufmann S.H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999, 68:383-424.
24. Fischer U., Jänicke R.U., Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 2003, 10:76-100.
25. Sahara S., Aoto M., Eguchi Y., Imamoto N., Yoneda Y., Tsujimoto Y. Acinus is a caspase-3-activated protein required for apoptotic chromatin condensation. Nature 1999, 401:168-173.
26. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 2009, 61:1203-1213.
27. Muvaffak A., Gurhan I., Hasirci N. Prolonged cytotoxic effect of colchicine released from biodegradable microspheres. JBiomed Mater Res B Appl Biomater 2004, 71:295-304.
28. Lin R., Ng L.S., Wang C.H. Invitro study of anticancer drug doxorubicin in PLGA-based microparticles. Biomaterials 2005, 26:4476-4485.
29. Momparler R.L., Karon M., Siegel S.E., Avila F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res 1976, 36:2891-2895.
30. Hortobágyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs 1997, 54:1-7.
31. Lee T.K., Lau T.C., Ng I.O. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother Pharmacol 2002, 49:78-86.
32. Tsang W.P., Chau S.P., Kong S.K., Fung K.P., Kwok T.T. Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci 2003, 73:2047-2058.
33. Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993, 362:849-852.
34. Lotem J., Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 1993, 82:1092-1096.
35. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74:957-967.
36. Bakalkin G., Yakovleva T., Selivanova G., Magnusson K.P., Szekely L., Kiseleva E., et al. p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc Natl Acad Sci U S A 1994, 91:413-417.
37. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992, 71:543-546.
38. Slee E.A., O'Connor D.J., Lu X. To die or not to die: how does p53 decide?. Oncogene 2004, 23:2809-2818.
39. Guan Y.S., La Z., Yang L., He Q., Li P. p53 gene in treatment of hepatic carcinoma: status quo. World J Gastroenterol 2007, 13:985-992.
40. Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E., et al. p53 status and the efficacy of cancer therapy invivo. Science 1994, 266:807-810.
41. Galmarini C.M., Falette N., Tabone E., Levrat C., Britten R., Voorzanger-Rousselot N., et al. Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity. Br J Cancer 2001, 85:902-908.
42. Galmarini C.M., Clarke M.L., Falette N., Puisieux A., Mackey J.R., Dumontet C. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 2002, 97:439-445.
43. Millau J.F., Bastien N., Drouin R. P53 transcriptional activities: a general overview and some thoughts. Mutat Res 2009, 681:118-133.
44. Whibley C., Pharoah P.D., Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009, 9:95-107.